Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Astria Therapeutics Inc. | CAT-2054 | Hypercholesterolemia | Phase 2a | Trial Discontinued | Oral | Cardiology |
| Astria Therapeutics Inc. | Navenibart (STAR-0215) - (ORBIT-EXPANSE) | Hereditary angioedema (HAE) | Phase 3 | Ongoing | Subcutaneous | Genetic Disorder |
| Astria Therapeutics Inc. | Navenibart (STAR-0215) - (ALPHA-SOLAR) | Hereditary Angioedema | Phase 3 | Data Released | Subcutaneous | Genetic Disorder |
| AtaiBeckley Inc. | PCN-101 | Treatment Resistant Depression (TRD) | Phase 2a | Ongoing | Intravenous | Psychiatric |
| AtaiBeckley Inc. | VLS-01 - (Elumina) | Treatment Resistant Depression | Phase 2 | Ongoing | Oral | Psychiatric |
| AtaiBeckley Inc. | Inidascamine (formerly RL-007) | Cognitive Impairment Associated with Schizophrenia | Phase 2b | Ongoing | Oral | Psychiatric |
| AtaiBeckley Inc. | COMP360 - (COMPASS) | Treatment Resistant Depression (TRD) | Phase 2b | Data Released | Oral | Psychiatric |
| AtaiBeckley Inc. | PCN-101 (R-ketamine) | Drug-drug interaction (DDI) | Phase 2a | Ongoing | Intravenous | N/A |
